Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis

被引:114
作者
Wessels, Judith A. M.
Kooloos, Wouter M.
de Jonge, Robert
de Vries-Bouwstra, Jeska K.
Allaart, Cornelia F.
Linssen, Annelies
Collee, Gerard
de Sonnaville, Peter
Lindemans, Jan
Huizinga, Tom W. J.
Guchelaar, Henk-Jan
机构
[1] Leiden Univ, Med Ctr, NL-2300 RC Leiden, Netherlands
[2] Erasmus Univ, Med Ctr, NL-3000 DR Rotterdam, Netherlands
[3] Vrije Univ Amsterdam, Med Ctr, NL-1081 HV Amsterdam, Netherlands
[4] Fdn Appl Rheumatol Res, Leiden, Netherlands
来源
ARTHRITIS AND RHEUMATISM | 2006年 / 54卷 / 09期
关键词
D O I
10.1002/art.22032
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Among patients with rheumatoid arthritis (RA), there is a high degree of interindividual variability in the degree of response to methotrexate (MTX) treatment. This study was undertaken to explore polymorphisms in genes contributing to antiinflammatory adenosine release as novel predictors of MTX treatment outcome. Methods. In 205 patients with newly diagnosed RA, 5 polymorphisms in 5 genes coding for enzymes related to the release of adenosine were analyzed. All patients received standardized MTX treatment (up to 25 ing per week orally), combined with folic acid. MTX efficacy was evaluated by the Disease Activity Score (DAS) and compared among genotypes. The association between MTX-related adverse events and genotype was also assessed. The following polymorphisms were determined: AMPD1 34C > T, ATIC 347C > G, ITPA 94C > A, MTR 2756A > G, and MTRR 66A > G. When significant differences were found by chi-square analysis, odds ratios (ORs) and 95% confidence intervals were calculated. Results. Patients carrying the AMPD1 34T allele, ATIC 347CC, or ITPA 94CC were more likely to have a good clinical response, as defined by a DAS of <= 2.4 (OR [95% confidence interval] 2.1 [1.0-4.5], 2.5 [1.3-4.7], and 2.7 [1.1-8.1], respectively). The likelihood of a good clinical response was increased if patients possessed all 3 favorable genotypes (OR 27.8 [95% confidence interval 3.2-250]). Regarding toxicity, only ATIC G allele carriers experienced a greater frequency of adverse events (OR 2.0 [95% confidence interval 1.1-3.7]). Conclusion. Polymorphisms in the AMPD1, ATIC, and ITPA genes are associated with good clinical response to MTX treatment. These findings indicate that genotyping may help in the identification of patients who will benefit most from MTX treatment and may assist clinicians in making treatment decisions regarding patients with recent-onset RA.
引用
收藏
页码:2830 / 2839
页数:10
相关论文
共 49 条
[41]   Pharmacogenetics of outcome in children with acute lymphoblastic leukemia [J].
Rocha, JCC ;
Cheng, C ;
Liu, W ;
Kishi, S ;
Das, S ;
Cook, EH ;
Sandlund, JT ;
Rubnitz, J ;
Ribeiro, R ;
Campana, D ;
Pui, CH ;
Evans, WE ;
Relling, MV .
BLOOD, 2005, 105 (12) :4752-4758
[42]   Therapeutic strategies in early rheumatoid arthritis [J].
Smolen, JS ;
Machold, KP .
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2005, 19 (01) :163-177
[43]   Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses [J].
Urano, W ;
Taniguchi, A ;
Yamanaka, H ;
Tanaka, E ;
Nakajima, H ;
Matsuda, Y ;
Akama, H ;
Kitamura, Y ;
Kamatani, N .
PHARMACOGENETICS, 2002, 12 (03) :183-190
[44]  
VANDERHEIJDE DMFM, 1993, J RHEUMATOL, V20, P579
[45]   Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis - Comparison with the preliminary American College of Rheumatology and the World Health Organization International League Against Rheumatism criteria [J].
vanGestel, AM ;
Prevoo, MLL ;
vantHof, MA ;
vanRijswijk, MH ;
vandePutte, LBA ;
vanRiel, PLCM .
ARTHRITIS AND RHEUMATISM, 1996, 39 (01) :34-40
[46]   A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up [J].
Verstappen, SMM ;
Albada-Kuipers, GAV ;
Bijlsma, JWJ ;
Blaauw, AAM ;
Schenk, Y ;
Haanen, HCM ;
Jacobs, JWG .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (01) :38-43
[47]   Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year [J].
Verstappen, SMM ;
Jacobs, JWG ;
Bijlsma, JWJ ;
Heurkens, AHM ;
van Booma-Frankfort, C ;
ter Borg, EJ ;
Hofman, DM ;
van der Veen, MJ .
ARTHRITIS AND RHEUMATISM, 2003, 48 (07) :1797-1807
[48]   Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis [J].
Weisman, MH ;
Furst, DE ;
Park, GS ;
Kremer, JM ;
Smith, KM ;
Wallace, DJ ;
Caldwell, JR ;
Dervieux, T .
ARTHRITIS AND RHEUMATISM, 2006, 54 (02) :607-612
[49]  
WESSELS JA, 2006, ARTHRITIS RHEUM, V54, P1807